ERBB2 and breast cancer: In conclusion, ARX788, a site-specific homogeneous ADC, demonstrated intracranial efficacy for active BrMs in HER2-positive breast cancer patients previously treated with trastuzumab, taxanes, and TKI-containing treatments.